Polymyalgia Rheumatica: a Common Disease in Seniors

Area of Science:

• Rheumatology
• Immunology
• Geriatrics

Background:

• Polymyalgia rheumatica (PMR) is a prevalent inflammatory condition in individuals over 50.
• Characterized by proximal pain and stiffness, PMR can be mimicked by other disorders like giant cell arteritis (GCA).
• Current treatments, primarily glucocorticosteroids (GC), have variable efficacy and significant toxicity in older adults.

Purpose of the Study:

• To review the latest findings in polymyalgia rheumatica (PMR).
• To cover etiologic factors, genetic associations, diagnostic methods, and treatment advancements.
• To highlight the need for novel therapeutic strategies due to limitations of current GC-based regimens.

Main Methods:

• Literature review of recent findings in PMR.
• Analysis of advancements in diagnostic and monitoring tools.
• Exploration of emerging therapeutic targets and strategies.

Main Results:

• PMR shares pathophysiological links with GCA, driving new research.
• Novel therapeutic targets, including IL-6 blocking agents, are under investigation.
• Current treatments pose significant morbidity risks, emphasizing the need for alternatives.

Conclusions:

• Understanding PMR pathophysiology is advancing treatment options.
• New immunopathologic targets offer promise for future PMR therapies.
• Developing safer and more effective treatments for PMR is crucial for improving patient outcomes.